Shiravani Zahra, Atbaei Sana, Namavar Jahromi Bahia, Hajisafari Tafti Mojgan, Moradi Alamdarloo Shaghayegh, Poordast Tahereh, Noori Adel, Forouhari Sedighe, Sabetian Soudabeh
Gynecology Oncology Division, Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Science, Shiraz, Iran.
Maternal-Fetal Medicine Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Int J Reprod Biomed. 2022 Apr 21;20(3):177-184. doi: 10.18502/ijrm.v20i3.10709. eCollection 2021 Mar.
Ectopic pregnancy (EP) is one of the major causes of maternal mortality during the first trimester of pregnancy.
Four treatment methods for EP including single-dose methotrexate (SD-MTX), double-dose methotrexate, expectant and surgical management were considered.
In this cross-sectional study, the clinical characteristics of 365 women aged 15-44 yr who had been diagnosed with EP were reviewed from March 2017 to March 2019 in hospitals affiliated to Shiraz University of Medical Sciences, Shiraz, Iran. Receiver operating characteristics curves were plotted to determine the cut-off points for size of ectopic mass and beta-human chorionic gonadotropin (β-hCG) that suitably discriminated between double-dose methotrexate and surgery management.
The most common site of EP was adnexa. According to the receiver operating characteristics analysis, surgery was the best plan for the women with an ectopic mass 34.50 mm in diameter or with an initial β-hCG level 6419 mIU/ml. The β-hCG levels in the women successfully treated with SD-MTX were significantly lower than in those with failed treatment (p = 0.02). The SD-MTX group had a higher success rate and significantly shorter duration of hospitalization, and so this was a more effective medical treatment in comparison with the double-dose protocol.
Surgery is proposed as the best option for the cases with large ectopic mass or high β-hCG level. SD-MTX had a higher success rate and shorter hospital stay than the double-dose protocol, and so was found to be an efficient and safe alternative. Further randomized clinical trials with larger sample sizes are recommended to validate the current results.
异位妊娠(EP)是妊娠早期孕产妇死亡的主要原因之一。
探讨单剂量甲氨蝶呤(SD-MTX)、双剂量甲氨蝶呤、期待治疗和手术治疗这四种EP治疗方法。
在这项横断面研究中,回顾了2017年3月至2019年3月在伊朗设拉子医科大学附属医院确诊为EP的365名15 - 44岁女性的临床特征。绘制受试者工作特征曲线以确定异位包块大小和β-人绒毛膜促性腺激素(β-hCG)的截断点,以区分双剂量甲氨蝶呤和手术治疗。
EP最常见的部位是附件。根据受试者工作特征分析,对于直径≥34.50 mm的异位包块或初始β-hCG水平≥6419 mIU/ml的女性,手术是最佳方案。成功接受SD-MTX治疗的女性的β-hCG水平显著低于治疗失败的女性(p = 0.02)。SD-MTX组的成功率更高,住院时间显著更短,因此与双剂量方案相比,这是一种更有效的药物治疗。
对于异位包块大或β-hCG水平高的病例,建议手术作为最佳选择。SD-MTX比双剂量方案成功率更高,住院时间更短,因此被认为是一种有效且安全的替代方案。建议进一步进行更大样本量的随机临床试验以验证当前结果。